{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic", "query": { "condition": "Malignant Melanoma, Metastatic" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1013, "total_pages": 102, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T15:03:43.708Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04068896", "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Metastatic Castration-resistant Prostate Cancer", "Bladder Cancer", "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Gastric Cancer", "Esophageal Cancer", "Ovarian Cancer", "Head Neck Squamous Cell Carcinoma", "Prostate Cancer" ], "interventions": [ { "name": "NGM120 30mg", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg", "type": "BIOLOGICAL" }, { "name": "NGM120 30mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg Q3W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2019-10-16", "completion_date": "2024-01-08", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 20, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068896" }, { "nct_id": "NCT05383170", "title": "A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Breast Cancer", "Advanced Melanoma" ], "interventions": [ { "name": "CyPep-1", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/ML [KEYTRUDA®]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytovation AS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-03-21", "completion_date": "2024-09-23", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05383170" }, { "nct_id": "NCT02117362", "title": "Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "1 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "2 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "4 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "8 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-05-08", "completion_date": "2018-11-28", "has_results": false, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02117362" }, { "nct_id": "NCT03472586", "title": "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Liver", "Metastatic Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Embolization Therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-05-02", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472586" }, { "nct_id": "NCT01236573", "title": "Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Skin Cancer", "Metastatic Melanoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-12 transduced TIL", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 34, "start_date": "2010-10", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2015-11-26", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01236573" }, { "nct_id": "NCT01014351", "title": "Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2010-02", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-03-26", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 12, "location_summary": "Fort Myers, Florida • Gainesville, Georgia • Evansville, Indiana + 9 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01014351" }, { "nct_id": "NCT04903119", "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "BRAF Gene Mutation" ], "interventions": [ { "name": "Nilotinib 100mg", "type": "DRUG" }, { "name": "Nilotinib 200mg", "type": "DRUG" }, { "name": "Nilotinib 300mg", "type": "DRUG" }, { "name": "Nilotinib 400mg", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rina Plattner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-06-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Easton", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903119" }, { "nct_id": "NCT04941430", "title": "7T MRI Scan for the Early Detection of Melanoma Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Magnetic Resonance Imaging using 7 Tesla MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-06-25", "completion_date": "2025-01-10", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04941430" }, { "nct_id": "NCT00414765", "title": "Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2008-09-03", "completion_date": "2010-03-28", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 4, "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00414765" }, { "nct_id": "NCT05169437", "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Breast Tumor", "Colon Tumor, Malignant", "Lung Tumor", "Urologic Cancer", "Pancreatic Cancer", "Melanoma", "Metastatic Cancer", "Locally Advanced Solid Tumor", "Esophageal Cancer", "Endometrial Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-03-15", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-06-07T15:03:43.708Z", "location_count": 80, "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169437" } ] }